

DAFTAR PUSTAKA

- Badiee, P., Alborzi, A., Moeini, M., Haddadi., P., Farshad, S., Japoni, A., *et al.*, 2012, Antifungal Susceptibility of the *Aspergillus* Species by Etest and CLSI Reference Methods, *Archives of Iranian Medicine*, 15 (7).
- Clark, G., Kasten, F. H. & Conn, H. J., 1983, *History of staining*, Williams & Wilkins, Philadelphia, United States.
- Deacon, J. W., 2006, *Fungal Biology, sixth edition*, 21-23, Blackwell Publishing Ltd., Victoria, Australia.
- Ellis, D. & Herman, R., 2003, *Mold Pictures: Aspergillus fumigatus*, <http://www.mold.ph/aspergillus-fumigatus.htm> (diakses tanggal 29 Januari 2014).
- Ellis, M., Frampton, C., Joseph, J., Alizadeh, H., Kristensen, J., Hauggard, A., *et al.*, 2006, An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy, *Journal of Medical Microbiology*, 55, 1357–1365.
- Fortu'n, J., Martin-Da 'Villa, P., Montejo, M., Munoz, P., Cineros, JM., Ramos, A., *et al.*, 2009, Prophylaxis With Caspofungin for Invasive Fungal Infections in High-Risk Liver Transplant Recipients, *Clinical And Translational Research*, 87 (3), 424-434.
- Fothergill, A. W., 2012, *Antifungal Susceptibility Testing: Clinical Laboratory and Standards Institute (CLSI) Methods*, LLC, Springer Science & Business Media.
- Ghannoum, M. A. & Rice, L. B., 1999, Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance, *Clinical Microbiology Reviews*, 12 (4).
- Hilado, A. L. E., 2005, *Mold Pictures: Aspergillus fumigatus*, <http://www.mold.ph/aspergillus-fumigatus.htm> (diakses tanggal 29 Januari 2014).
- Henrici, A.T., 1948, *The Biology of Bacteria*, D.C.Heath and Company, Houghton Mifflin, United States.
- Herbrecht, R., Ursula, F. C., Bertrand, G., Patricia, R., Anne, T. & Catherine, C., 2007, Treatment of invasive *Candida* and invasive *Aspergillus* infections in adult haematological patients, *European Journal of Cancer*, 5, 49 –59.

- Ingroff, E., Skaggs, A., Iqbal, E., Pfaller, M.S., Rinaldi, M., Fothergill, A., *et al.*, 2007, Multicenter Evaluation of a New Disk Agar Diffusion Method for Susceptibility Testing of Filamentous Fungi with Voriconazole, Posaconazole, Itraconazole, Amphotericin B, and Caspofungin, *Journal of Clinical Microbiology*, 45 (6).
- Jawetz, E., Melnick, J. & Adelberg, E., 1996, *Mikrobiologi Kedokteran*, Jakarta, EGC.
- Jawetz, M. & Adelberg, E., 2007, *Medical Microbiology*, USA, The Mc.Graw-Hill Companies Inc.
- Johnson, E.M., Szekely, A. & Warnock, D.W., 1998, In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi, *Journal of Antimicrobial Chemotherapy*, 42.
- Karthaus, M., 2011, Prophylaxis and Treatment of Invasive Aspergillosis with Voriconazole, Posaconazole, and Caspofungin, *European Journal of Medical Research*, 16, 145-152.
- Kee, Joyce L. & Hayes, Evelyn R., 1996, *Farmakologi: Pendekatan Proses Keperawatan*, Jakarta, EGC.
- Kuzucu, C., Rapino, B., Mc.Dermott, L. & Hadley, S., 2004, Comparison of the Semisolid Agar Antifungal Susceptibility Test with the NCCLS M38-P Broth Microdilution Test for Screening of Filamentous Fungi, *Journal of Clinical Microbiology*, 42 (3).
- Lass-Florla, C., Koflera, G., Kropshofer, G., Hermansd, J., Kreczyb, A., Diericha, M. P, *et al.*, 1998, In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis, *Journal of Antimicrobial Chemotherapy*, 42.
- Letscher-Bru, V. & Herbrecht, R., 2003, Caspofungin: the first representative of a new antifungal class, *Journal of Antimicrobial Chemotherapy*, 52.
- Linares, M. J., Charriel, G., Sol'S, F., Rodriguez, J. R., Ibarra, A. & Casal, M., 2005, Susceptibility of Filamentous Fungi to Voriconazole Tested by Two Microdilution Methods, *Journal of Clinical Microbiology*, 43 (1).
- Maertens, J., Raad, I., Petrikkos, G., Boogaerts, M., Selleslag, D., Petersen, F. B, *et al.*, 2004, Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy, *Clinical Infectious Diseases*, 39.
- Manavathu, E. K., Alangaden, G. J. & Chandrasekar, P. H., 2003, Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against *Aspergillus fumigatus*, *Journal of Antimicrobial Chemotherapy*, 51.

- Mehrotra, R. S. & Aneja, K. R., 1990, *An Introduction to Mycology*, Wiley, New York, Wiley Eastern Limited.
- Mellado, E., Alcazar-Fuoli, L., Cuenca-Estrella, M. & Rodriguez-Tudela, J.L., 2011, Role of *Aspergillus lentulus* 14- α Sterol Demethylase (Cyp51A) in Azole Drug Susceptibility, *Antimicrobial Agents and Chemotherapy*, 55 (12), 5459–5468.
- Njunda, A. L., Ewang, A. A., Kamga, L. H. F., Nsagha, D. S., Assob, J. C., Ndah, D. A., *et al.*, 2012, Respiratory Tract Aspergillosis in the Sputum of Patients Suspected of Tuberculosis in Fako Division-Cameroon, *Journal of Microbiology Research*, 2 (4), 68-72.
- Oakley, K. L., Moore, C. B. & Denninga, D. W., 1998, In-vitro activity of voriconazole against *Aspergillus spp.* and comparison with itraconazole and amphotericin B, *Journal of Antimicrobial Chemotherapy*, 42.
- Pasanen, A. L., 1991, Laboratory studies on the relationship between fungal growth and atmospheric temperature and humidity, *Environment International*, 17.
- Penelope, D. B. & Kieren, A., 2006, Aspergillosis: Spectrum of Disease, Diagnosis, and Treatment, *Infectious Disease Clinics of North America*, 20.
- Perea, S., Gonzales, G., Fothergill, A. W., Kirkpatrick, W. R., Rinaldi, M. & Patterson, T. F., 2002, In Vitro Interaction of Caspofungin Acetate with Voriconazole against Clinical Isolates of *Aspergillus spp.*, *Antimicrobial Agents and Chemotherapy*, 46 (9).
- Pfaller, M. A., Messer, S. A., Hollis, R. J. & Jones, R. N., 2002, Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of *Aspergillus spp.* and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000, *Antimicrobial Agents and Chemotherapy*, 46 (4), 1032–1037.
- Reiss, E., Shadomy, H.J. & Lyon, G.M., 2011, *Fundamental Medical Mycology*, New York, Wiley.
- Siau, H. & Kerridge, A. D., 1998, The effect of antifungal drugs in combination on the growth of *Candida glabrata* in solid and liquid media, *Journal of Antimicrobial Chemotherapy*, 41.
- Therese, K., Bagyalakshmi, R., Madhavan, H. & Deepa, P., 2006, In-Vitro Susceptibility Testing by Agar Dilution Method to Determine the Minimum Inhibitory Concentrations of Amphotericin B, Fluconazole and Ketoconazole Against Ocular Fungal Isolates, *Indian Journal of Medical Microbiology*, 24 (4).

- Thompson, G. R. & Patterson, T. F., 2008, *Pulmonary Aspergillosis*, Seventh Avenue, New York, Thieme Medical Publishers, Inc.
- Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., *et al.*, 2008, Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America, *IDSA Guidelines for Aspergillosis*, 46.
- Winn, W. C. & Koneman, E. W., 2006, *Koneman's Color Atlas and Textbook of Diagnostic Microbiology*, Lippincott Williams & Wilkins, Philadelphia, United States.